SynthesisFrontiers in medicine2026
Transitioning from invasive to liquid biopsy techniques: a bibliometric analysis and prospective insights on biomarkers in lupus nephritis.
Synthesis in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lupus nephritis (LN) significantly contributes to morbidity and mortality in systemic lupus erythematosus (SLE) patients. Although renal biopsy is the diagnostic "gold standard," its invasiveness limits ongoing disease monitoring. Recently, research has focused on non-invasive "liquid biopsy" biomarkers, especially in urine. This study uses bibliometric methods to analyze the development and trends in LN biomarker research, highlighting recent advancements and future directions. Methods: We collected original research articles on LN biomarkers from the Web of Science Core Collection and PubMed databases from 2005 to 2024. We conducted a bibliometric analysis using CiteSpace, VOSviewer, and Bibliometrix, and included 2025 studies on urinary biomarkers, renal pathology, disease activity, and long-term outcomes. Results: The analysis encompassed 576 articles, revealing three distinct developmental phases in the field, accompanied by a notable surge in publications since 2016. China and the United States are the top contributors, with the U.S. leading in citation impact and collaboration. The most active journal functions as a crucial repository of knowledge. Keyword and citation analysis reveal a shift from traditional immunological markers to non-invasive urinary biomarkers, such as MCP-1, NGAL, CD163, and complement-related molecules, alongside the adoption of multi-omics approaches and predictive models. Conclusion: Research on LN biomarkers is moving from discovery to clinical application. Advances in single-cell and spatial omics are shifting focus from peripheral biomarkers to renal molecular phenotypes, supporting "liquid biopsy" strategies. Future efforts will emphasize AI-driven multi-omics integration, minimal biomarker panels, and cross-ethnic validation to develop a precise, non-invasive LN monitoring system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.